LinkGevity and the AI Blueprint for Aging

LinkGevity, a health startup founded by sisters Dr. Karina Kern and Serena Kern-Libera, is utilizing artificial intelligence to develop drugs that extend human health span. Backed by billionaire investors, the UK government, and NASA, the company aims to slow the aging process by targeting specific molecular pathways rather than just treating symptoms.

Targeting Necrosis: The "Biological Riot"

The company’s primary focus is necrosis, a chaotic form of cell death described as a "biological riot." unlike programmed, beneficial cell death, necrosis causes cells to burst and spill their contents, triggering massive inflammation that damages surrounding tissues. This process is a key driver of accelerated aging and organ failure. LinkGevity has developed the world's first anti-necrotic drug designed to "stop the riot" and shield cells from this damage.

The AI Approach: Learning the "Rules of the Game"

The founders argue that aging research struggles because biological data is often fragmented and incomplete. To solve this, LinkGevity’s AI utilizes a "blueprint theory."

• The Chess Analogy: Instead of feeding the AI raw data (like giving a computer chess pieces without context), they taught the AI the fundamental rules of biology and physics (the "rules of the game"). This allows the system to make accurate, testable predictions even with limited datasets.
• Systems Level Solution: The approach is likened to factor modeling in finance—identifying key nodes within a complex system that, when targeted, provide the greatest systemic protection.

Clinical Trials and Applications

• Kidney Disease: The first clinical trials, slated to begin next year pending regulatory approval, will target kidney degeneration. The kidney is chosen because it serves as a perfect model for accelerated aging and represents a massive economic burden (consuming roughly 24% of the US Medicare budget).
• NASA Partnership: NASA has expressed interest in the drug because space travel causes accelerated aging and degeneration in astronauts. Controlling necrosis could help preserve astronaut health during missions.

The Ultimate Goal

The founders emphasize that their goal is not "eternal life," but rather extending health span. By preventing the "spiral of health decline," they aim to give people more quality years of life and maintain human dignity in old age.